FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis - PubMed (original) (raw)
doi: 10.1359/JBMR.0301264. Epub 2003 Dec 29.
Affiliations
- PMID: 15040831
- DOI: 10.1359/JBMR.0301264
Free article
FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis
Takashi Shimada et al. J Bone Miner Res. 2004 Mar.
Free article
Abstract
We analyzed the effects of an FGF-23 injection in vivo. FGF-23 caused a reduction in serum 1,25-dihydroxyvitamin D by altering the expressions of key enzymes for the vitamin D metabolism followed by hypophosphatemia. This study indicates that FGF-23 is a potent regulator of the vitamin D and phosphate metabolism.
Introduction: The pathophysiological contribution of FGF-23 in hypophosphatemic diseases was supported by animal studies in which the long-term administration of recombinant fibroblast growth factor-23 reproduced hypophosphatemic rickets with a low serum 1,25-dihydroxyvitamin D [1,25(OH)2D] level. However, there is no clear understanding of how FGF-23 causes these changes.
Materials and methods: To elucidate the molecular mechanisms of the FGF-23 function, we investigated the short-term effects of a single administration of recombinant FGF-23 in normal and parathyroidectmized animals.
Results: An injection of recombinant FGF-23 caused a reduction in serum phosphate and 1,25(OH)2D levels. A decrease in serum phosphate was first observed 9 h after the injection and was accompanied with a reduction in renal mRNA and protein levels for the type IIa sodium-phosphate cotransporter (NaPi-2a). There was no increase in the parathyroid hormone (PTH) level throughout the experiment, and hypophosphatemia was reproduced by FGF-23 in parathyroidectomized rats. Before this hypophosphatemic effect, the serum 1,25(OH)2D level had already descended at 3 h and reached the nadir 9 h after the administration. FGF-23 reduced renal mRNA for 25-hydroxyvitamin D-1alpha-hydroxylase and increased that for 25-hydroxyvitamin D-24-hydroxylase starting at 1 h. In addition, an injection of calcitriol into normal mice increased the serum FGF-23 level within 4 h.
Conclusions: FGF-23 regulates NaPi-2a independently of PTH and the serum 1,25(OH)2D level by controlling renal expressions of key enzymes of the vitamin D metabolism. In conclusion, FGF-23 is a potent regulator of phosphate and vitamin D homeostasis.
Similar articles
- Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases.
Imanishi Y, Kobayashi K, Kawata T, Inaba M, Nishizawa Y. Imanishi Y, et al. Ther Apher Dial. 2007 Oct;11 Suppl 1:S32-7. doi: 10.1111/j.1744-9987.2007.00519.x. Ther Apher Dial. 2007. PMID: 17976083 Review. - Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism.
Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, Ono K, Kakitani M, Tomizuka K, Fujita T, Fukumoto S, Yamashita T. Shimada T, et al. Am J Physiol Renal Physiol. 2005 Nov;289(5):F1088-95. doi: 10.1152/ajprenal.00474.2004. Epub 2005 Jul 5. Am J Physiol Renal Physiol. 2005. PMID: 15998839 - Vitamin D metabolism in the kidney: regulation by phosphorus and fibroblast growth factor 23.
Perwad F, Portale AA. Perwad F, et al. Mol Cell Endocrinol. 2011 Dec 5;347(1-2):17-24. doi: 10.1016/j.mce.2011.08.030. Epub 2011 Sep 5. Mol Cell Endocrinol. 2011. PMID: 21914460 Review. - Vitamin D and type II sodium-dependent phosphate cotransporters.
Kido S, Kaneko I, Tatsumi S, Segawa H, Miyamoto K. Kido S, et al. Contrib Nephrol. 2013;180:86-97. doi: 10.1159/000346786. Epub 2013 May 6. Contrib Nephrol. 2013. PMID: 23652552 Review.
Cited by
- Association of hyperphosphatemia with renal prognosis in patients with autosomal dominant polycystic kidney disease.
Nitta K, Kataoka H, Manabe S, Makabe S, Akihisa T, Ushio Y, Seki M, Tsuchiya K, Hoshino J, Mochizuki T. Nitta K, et al. Clin Exp Nephrol. 2024 Sep 25. doi: 10.1007/s10157-024-02568-6. Online ahead of print. Clin Exp Nephrol. 2024. PMID: 39322826 - Effects of High Dose Bolus Cholecalciferol on Free Vitamin D Metabolites, Bone Turnover Markers and Physical Function.
Bowles SD, Jacques R, Hill TR, Eastell R, Walsh JS. Bowles SD, et al. Nutrients. 2024 Aug 29;16(17):2888. doi: 10.3390/nu16172888. Nutrients. 2024. PMID: 39275206 Free PMC article. Clinical Trial. - Crosstalk between kidney and bone: insights from CKD-MBD.
Suzuki K, Soeda K, Komaba H. Suzuki K, et al. J Bone Miner Metab. 2024 Jul;42(4):463-469. doi: 10.1007/s00774-024-01528-0. Epub 2024 Jul 26. J Bone Miner Metab. 2024. PMID: 39060498 Review. - FGF23 as a Potential Pathophysiological Factor in Peripheral Arterial Disease Associated with Chronic Kidney Disease.
Donate-Correa J, Martín-Núñez E, Hernández-Carballo C, González-Luis A, Mora-Fernández C, Martín-Olivera A, Rodríguez-Ramos S, Cerro-López P, López-Castillo Á, Delgado-Molinos A, López-Tarruella VC, Navarro-González JF. Donate-Correa J, et al. Int J Mol Sci. 2024 May 17;25(10):5457. doi: 10.3390/ijms25105457. Int J Mol Sci. 2024. PMID: 38791495 Free PMC article. - The Molecular Mechanisms Underlying the Systemic Effects Mediated by Parathormone in the Context of Chronic Kidney Disease.
Maranduca MA, Cozma CT, Clim A, Pinzariu AC, Tudorancea I, Popa IP, Lazar CI, Moscalu R, Filip N, Moscalu M, Constantin M, Scripcariu DV, Serban DN, Serban IL. Maranduca MA, et al. Curr Issues Mol Biol. 2024 Apr 25;46(5):3877-3905. doi: 10.3390/cimb46050241. Curr Issues Mol Biol. 2024. PMID: 38785509 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases